TABLE 3 .
Characteristics of the 155 patients with single infection due to one of the three serotypes of C. neoformans
| Characteristic | Serotype A (n = 98.0) | Serotype D (n = 26.0) | Serotype AD (n = 31.0) | P |
|---|---|---|---|---|
| No. of males/total (%)a | 79/98 (80.6) | 21/26 (80.8) | 24/31 (77.4) | 0.957 |
| Age (yr) (mean ± SD) | 41.2 ± 11.9 | 45.8 ± 12.5 | 42.7 ± 12.5 | 0.217 |
| No. born in Africa/total (%) | 31/98 (31.6) | 0/26 (0) | 6/31 (19.4) | 0.001 |
| No. HIV infected/total (%) | 79/98 (80.6) | 16/26 (61.5) | 27/31 (87.1) | 0.063 |
| Mean CD4/mm3 ± SD for HIV-infected patients | 50 ± 82 | 44 ± 56 | 41 ± 54 | 0.866 |
| No. with abnormal neurology/total (%) | 40/98 (40.8) | 10/26 (38.7) | 15/31 (48.4) | 0.733 |
| No. with meningoencephalitis/total (%) | 82/95 (86.3) | 19/23 (82.6) | 26/28 (92.9) | 0.545 |
| No. with fungemia/total (%) | 42/94 (44.7) | 11/25 (44.0) | 11/28 (39.3) | 0.888 |
| No. with dissemination/total (%) | 60/98 (61.2) | 16/26 (61.5) | 12/31 (38.7) | 0.081 |
| No. with high serum antigen titer (≥512)/total (%) | 47/89 (52.8) | 8/23 (34.8) | 9/28 (32.1) | 0.083 |
| No. with high CSF antigen titer (≥512)/total (%) | 40/85 (47.1) | 6/17 (35.3) | 8/24 (33.3) | 0.398 |
| No. with abnormal brain imaging/total (%) | 28/80 (35.0) | 2/18 (11.1) | 11/27 (40.7) | 0.084 |
| No. with abnormal lung imaging/total (%) | 48/97 (49.5) | 11/23 (47.8) | 8/30 (26.7) | 0.088 |
| No. with AMB + 5FC as induction therapy/total (%)b | 54/98 (55.1) | 7/26 (26.9) | 14/31 (45.2) | 0.031 |
| No. with fluconazole as induction therapy/total (%) | 24/92 (26.1) | 11/24 (45.8) | 12/29 (41.4) | 0.086 |
| No. with mycological failure at day 15/total (%)c | 33/77 (42.9) | 7/22 (31.8) | 4/24 (16.7) | 0.059 |
| No. with CSF mycological failure at day 15/total (%)d | 31/66 (47.0) | 6/17 (35.3) | 3/23 (13.0) | 0.013 |
| No. who died within 90 days after diagnosis/total (%) | 21/82 (25.6) | 7/22 (31.8) | 7/25 (28.0) | 0.812 |
a
Total number of patients evaluated or for whom the information was available.
b
AMB, amphotericin B; 5FC, flucytosine.
c
Persistence of viable cryptococci in cultured samples.
d
Persistence of viable cryptococci in cerebrospinal fluid samples.